Neratinib is a more potent inhibitor of proliferation and downstream signaling pathways than lapatinib or afatinib in cell line models of HER2+ breast cancer and can potentiate the effects of trastuzumab in trastuzumab-sensitive HER2+ breast cancer cell lines. Here, ERBB2 is linked to breast carcinoma.